REGN250509C625000
- 0.76
- -1.84-70.77%
Regeneron Pharmaceuticals Newsroom
Today's Analyst Rating | Berkshire Hathaway-B Price Target Raised to $606 by UBS, Wells Fargo Cuts Its Price Target Cut on Chevron to $164
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $958
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $800
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $810
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'Arguably The Most Innovative Biopharma Company I've Seen In The Last Two Decades'
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences
Regeneron Pharma Is Maintained at Buy by Guggenheim
Regeneron Pharma To Present New And Updated Data From Oncology And Hematology Portfolio At ASCO Annual Meeting
Express News | Regeneron to Highlight Advances at Asco With Phase 3 Adjuvant Libtayo® (Cemiplimab) Cscc Updates and Promising Early Blood Cancer Data With Linvoseltamab Combination
Express News | Dupixent® (Dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $587 to $940
Regeneron (REGN) Gets a Buy From Evercore ISI
Regeneron Shares Are Up Today: What's Going On?
Regeneron Shares Are Trading Higher After Falling on Tuesday Following Wore-than-expected Q1 Financial Results.
Express News | Regeneron Shares Are Trading Higher After Falling on Tuesday Following Wore-than-expected Q1 Financial Results
Guggenheim Cuts Regeneron Pharmaceuticals' Price Target to $810 From $940
Express News | Goldman Sachs Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $804
Regeneron Pharma Is Maintained at Overweight by Wells Fargo